Insertable cardiac monitor for remote care nets FDA clearance
Medtronic announced it received FDA clearance and a CE mark for its insertable cardiac monitor with remote programming.
The new system (LINQ II, Medtronic) also has improved longevity of up to 4.5 years when used at normal settings, according to a press release from the company.
“In the current COVID-19 environment, the LINQ II system offers patients a seamless way to experience ongoing connectivity between their device and their physician, while reducing the need for in-office visits,” Rob Kowal, MD, PhD, chief medical officer of the Cardiac Rhythm and Heart Failure division at Medtronic, said in the release. “LINQ II gives physicians actionable data to help diagnose underlying heart conditions and define treatment protocols for patients with atrial fibrillation or other abnormal heart rhythms.”
The insertable cardiac monitor offers remote programming and remote patient management, which may reduce the need for patients for office visits to have device settings adjusted, the company stated in the release.
According to the release, patients can choose to use their smartphones to automatically transfer device data via the company’s mobile app (MyCareLink Heart, Medtronic) or to transmit data via a specialized communicator (MyCareLink Relay Home Communicator, Medtronic).
The device will be made commercially available in the U.S. and Europe later this summer.
Collapse
Read more about